{"id":795068,"date":"2024-12-16T08:36:24","date_gmt":"2024-12-16T13:36:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/"},"modified":"2024-12-16T08:36:24","modified_gmt":"2024-12-16T13:36:24","slug":"cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/","title":{"rendered":"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests<\/b><\/p>\n<p><i>CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement.<\/i><\/p>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cdio.ai%2F&amp;esheet=54167246&amp;newsitemid=20241216295360&amp;lan=en-US&amp;anchor=Cardio+Diagnostics+Holdings%2C+Inc.&amp;index=1&amp;md5=e2c5329870693f1834455b0f624efb8f\">Cardio Diagnostics Holdings, Inc.<\/a> (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company\u2019s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare &amp; Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the \u2018gapfill\u2019 pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing for PrecisionCHD and Epi+Gen CHD based on actual cost data from Cardio Diagnostics. The Medicare contractors will report to CMS preliminary gapfill pricing for calendar year 2025 by April 1, 2025.<\/p>\n<p>\n\u201cReceiving this final determination is a crucial step for our innovative solutions to help improve the risk assessment, diagnosis, management and monitoring of coronary heart disease (CHD) for Medicare patients,\u201d said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. \u201cThis milestone brings us closer to addressing the significant unmet needs in cardiovascular care for the Medicare population, enabling clinicians to better personalize treatment strategies and ultimately improve patient outcomes.\u201d<\/p>\n<p>\nCardiovascular disease is the leading <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Ffastats%2Fheart-disease.htm&amp;esheet=54167246&amp;newsitemid=20241216295360&amp;lan=en-US&amp;anchor=cause+of+death+in+the+United+States&amp;index=2&amp;md5=0eba15b555fecb0051d15a7252473b0a\">cause of death in the United States<\/a>, including among Americans over 65 years old. In 2022, the number of deaths due to heart disease was 702,880, with a mortality rate of 211 deaths per 100,000 population. Coronary heart disease, the most common type of heart disease, claimed 371,506 lives. PrecisionCHD is an AI-powered blood test that aids in the diagnosis of coronary heart disease (CHD) by evaluating genetic and epigenetic markers. Epi+Gen CHD assesses the three-year risk for a CHD event, including heart attacks, using a similar AI-driven integrated genetic-epigenetic approach. Both tests received dedicated CPT Proprietary Laboratory Analysis (PLA) codes from the American Medical Association, 0439U for Epi+Gen CHD and 0440U for PrecisionCHD, that were effective on April 1, 2024.<\/p>\n<p><b>About Cardio Diagnostics<\/b><\/p>\n<p>\nCardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (&#8220;Core Technology&#8221;) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cdio.ai%2F&amp;esheet=54167246&amp;newsitemid=20241216295360&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.cdio.ai%2F&amp;index=3&amp;md5=2f37e82c7465158b85cf8edeb0b00d44\">http:\/\/www.cdio.ai\/<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements and information included in this press release constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases \u201cwill\u201d, \u201cwill likely result,\u201d \u201cexpected to,\u201d \u201cwill continue,\u201d \u201canticipated,\u201d \u201cestimate,\u201d \u201cprojected,\u201d \u201cintend,\u201d \u201cgoal,\u201d or similar expressions are intended to identify \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company&#8217;s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2023, and Form 10-Q for the periods ended March 31, 2024, June 30, 2024 and September 30, 2024, under the heading \u201cRisk Factors\u201d in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company\u2019s financial performance and could cause the Company\u2019s actual results for future periods to differ materially from any opinions or statements expressed within this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241216295360\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241216295360\/en\/<\/a><\/span><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Investor Relations<br \/>\n<br \/>855-226-9991<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@cardiodiagnosticsinc.com\">investors@cardiodiagnosticsinc.com<\/a><\/p>\n<p><b>Media &amp; Public Relations:<br \/>\n<\/b><br \/>Kristen Hoff<br \/>\n<br \/>855-226-9991<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:pr@cardiodiagnosticsinc.com\">pr@cardiodiagnosticsinc.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Software Managed Care General Health Biometrics Technology Artificial Intelligence Genetics Health Technology Health Insurance Cardiology Biotechnology Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241216295360\/en\/2332932\/3\/585507300db2208f9f3402b0f0fe979a.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO&#8211;(BUSINESS WIRE)&#8211;Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company\u2019s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare &amp; Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the \u2018gapfill\u2019 pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-795068","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO&#8211;(BUSINESS WIRE)&#8211;Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company\u2019s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare &amp; Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the \u2018gapfill\u2019 pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing &hellip; Continue reading &quot;Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-16T13:36:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests\",\"datePublished\":\"2024-12-16T13:36:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/\"},\"wordCount\":775,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/\",\"name\":\"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-16T13:36:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/","og_locale":"en_US","og_type":"article","og_title":"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests - Market Newsdesk","og_description":"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO&#8211;(BUSINESS WIRE)&#8211;Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company\u2019s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare &amp; Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the \u2018gapfill\u2019 pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing &hellip; Continue reading \"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-16T13:36:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests","datePublished":"2024-12-16T13:36:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/"},"wordCount":775,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/","name":"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-16T13:36:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216295360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-determination-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=795068"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795068\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=795068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=795068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=795068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}